Skip to main content

Advertisement

Table 1 Differing characteristics of the studies comparing the response rates in HBeAg-positive patients

From: How to compare antivirals in the treatment of chronic hepatitis B?

  Pegylated-IFN-α2a, 180 μg once Weekly [8] Lamivudine 100 mg/d [810] Adefovir 10 mg/d [11] Entecavir 0.5 mg/d [9] Telbivudine 600 mg/d [10] Tenofovir 300 mg/d [12]
Mean age (years) 32.5 31.6 to 35 34 35 32 34
Male gender (%) 79 74 to 79 76 77 74 68
Asian race (%) 87 57 to 87 60 58 82 36
Patient number 271 272 to 463 171 354 399 176
Previous treatment Conventional IFN 11%, lamivudine 11% Conventional IFN 11%/IFN 13% and lamivudine 3%/NA IFN (24% among all arms) IFN 13% and lamivudine 3% NA IFN 17%, lamivudine or emtricitabine 5%
Baseline HBV-DNA (log10 cp/ml) 9.9 9.5 to 10.1 8.25 9.62 9.51 8.64
Baseline ALT 114.6 102 to 159 139 140.5 146 142
Baseline necro-inflammatory score NA 7.3 to 7.7 7.37 7.8 7 8.3
Baseline fibrosis score NA 2.2 to 2.3 1.64 2.3 2.2 2.3
Genotypes (%, A/B/C/D/others) 8/28/60/3/1 7/30/58/4/1 (ref 8) 28/22/25/15/11 (ref 9) NA 27/19/31/10/13 NA 24/14/25/32/5
Treatment duration (weeks) 48 48 to 52 48 48 52 48
Virological response criterion (HBV DNA level) <400 cp/ml <400 cp/ml (ref 8), <0.7 MEq/ml (ref 10), <300 cp/ml (ref 10) <300 cp/ml <0.7 MEq/ml <300 cp/ml <400 cp/ml
  1. IFN: interferon, NA: not available, MEq/ml: mili-equivalent/mililiter, cp/ml: copies/milliliter.